Malaria continues to exact heavy financial and socioeconomic burdens in several parts of the world, with 249 million cases and more than 630,000 deaths reported in 2022. Two-thirds of malaria-related deaths occur among children younger than 5 years.

Researchers from the Access to Advanced Health Institute and collaborating institutions have developed a promising new bivalent vaccine candidate that can protect against both yellow fever and Zika viruses. The study demonstrates that the vaccine elicits robust humoral and cellular immune responses in mice and hamsters and provides complete protection against lethal viral challenges.

Scientists at Institut Pasteur have gained new insights into how some people control HIV-1 replication after interruption of antiretroviral treatment (ART). The investigators found a fingerprint involved in long-term viral remission.

Varicella-zoster virus (VZV) causes chickenpox and shingles, while herpes simplex virus (HSV) is responsible for oral and genital herpes. Although current treatments mainly focus on inhibiting viral replication, there is a critical need for new therapies to address the limitations and side effects associated with existing treatments.

Harvard University has filed a lawsuit claiming the Trump administration’s freezing of its federal funding is unlawful and beyond the government’s authority. Announcing the move, Harvard’s president, Alan Garber, highlighted the impact of freezing $2.2 billion in grants – and the threat to freeze a further $1.1 billion – will have on the university’s biomedical research.

The U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and medical research charity Lifearc have announced a collaboration to develop an affordable and accessible monoclonal antibody (mAb) therapeutic for Crimean-Congo hemorrhagic fever virus (CCHFV).